Suzhou, Apr.9, 2021--Kintor Pharmaceutical Limited (stock code 9939.HK, “Kintor Pharmaceutical” or the “Company”), a clinical-stage biotechnology company developing small molecule and biological therapeutics, today announced two poster presentations of preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2021, including proxalutamide(GT0918) to treat COVID-19 and a c-Myc inhibitor to treat blood cancer.

In light of the COVID-19 pandemic, this year’s AACR annual meeting will be held in a virtual format over two weeks, April 10-15 and May 17-21.

■ E-Poster

Title: Repurposing 2nd generation androgen receptor antagonist Proxalutamide to treat COVID-19

Abstract Number: 711

Link: https://www.abstractsonline.com/pp8/#!/9325/presentation/1754

Title: Discovery of GT19077, a c-Myc/Max Protein-Protein Interaction(PPI) Small Molecule Inhibitor, and GT19506, a c-Myc protein degrader, for Targeting c-Myc-Driven Blood Cancers

Abstract Number:1265

Link: https://www.abstractsonline.com/pp8/#!/9325/presentation/2350

The AACR e-poster website will be launched on Saturday, April 10, the first day of the virtual AACR Annual Meeting. All e-posters will be made available for browsing on this date.